AbbVie ends its 11-year R&D partnership with Calico, the company that co-developed fosigotifator

Calico/Fosigotifator (ABBV-CLS-7262)

AbbVie ended its approximately 11-year partnership with Alphabet-backed Calico and is laying off chemists as it shifts away from small-molecule drugs toward injectable therapies and genetic medicines.

• Partnership lasted ~11 years; AbbVie and Calico co-developed fosigotifator for aging research and drug discovery.
• Strategic shift away from small-molecule oral drugs (pills) toward injectable therapies and complex genetic medicines.
• Layoffs involve chemists working on drug discovery; represents deprioritization of small-molecule longevity programs.